Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice
Primary cutaneous follicle centre lymphoma Microchapters |
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice On the Web |
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
FDA on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
CDC on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice in the news |
Blogs on Primary cutaneous follicle centre lymphoma Diagnostic Study of Choice |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Diagnostic Study of Choice
Study of choice
[Name of the investigation] is the gold standard test for the diagnosis of primary cutaneous follicle centre lymphoma.
OR
The following result of [gold standard test] is confirmatory of primary cutaneous follicle centre lymphoma:
- [Result 1]
- [Result 2]
OR
[Name of the investigation] must be performed when:
- The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
- A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of primary cutaneous follicle centre lymphoma.
OR
The diagnostic study of choice for primary cutaneous follicle centre lymphoma is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of primary cutaneous follicle centre lymphoma.
OR
There is no single diagnostic study of choice for the diagnosis of primary cutaneous follicle centre lymphoma, but primary cutaneous follicle centre lymphoma can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
primary cutaneous follicle centre lymphoma is primarily diagnosed based on the clinical presentation.
OR
Investigations:
- Among the patients who present with clinical signs of primary cutaneous follicle centre lymphoma, the [investigation name] is the most specific test for the diagnosis.
- Among the patients who present with clinical signs of primary cutaneous follicle centre lymphoma, the [investigation name] is the most sensitive test for diagnosis.
- Among the patients who present with clinical signs of primary cutaneous follicle centre lymphoma, the [investigation name] is the most efficient test for diagnosis.
The comparison of various diagnostic studies for primary cutaneous follicle centre lymphoma
Test | Sensitivity | Specificity |
---|---|---|
Test 1 | ...% | ...% |
Test 2 | ...% | ...% |
[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity
Diagnostic results
The following finding(s) on performing [investigation name] is(are) confirmatory for primary cutaneous follicle centre lymphoma:
- [Finding 1]
- [Finding 2]
Sequence of Diagnostic Studies
The [name of investigation] must be performed when:
- The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
- A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
- [Initial investigation]
- [2nd investigation]
Name of Diagnostic Criteria
It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.
primary cutaneous follicle centre lymphoma is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of primary cutaneous follicle centre lymphoma.
OR
There is no single diagnostic study of choice for primary cutaneous follicle centre lymphoma, though primary cutaneous follicle centre lymphoma may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of primary cutaneous follicle centre lymphoma is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of primary cutaneous follicle centre lymphoma is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
primary cutaneous follicle centre lymphoma may be diagnosed at any time if one or more of the following criteria are met:
- Criteria 1
- Criteria 2
- Criteria 3
OR
IF there are clear, established diagnostic criteria
The diagnosis of primary cutaneous follicle centre lymphoma is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of primary cutaneous follicle centre lymphoma is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of primary cutaneous follicle centre lymphoma is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
IF there are no established diagnostic criteria
There are no established criteria for the diagnosis of primary cutaneous follicle centre lymphoma.
Staging
Overview
Biopsy and pathologic studies are The staging of primary cutaneous follicle centre lymphoma is based on the International Society for Cutaneous Lymphomas (ISCL) / EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides / sezary syndrome.[1]
Staging
The staging of primary cutaneous follicle centre lymphoma is based on the International Society for Cutaneous Lymphomas (ISCL) / EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides / sezary syndrome.[1]
Name | Stage | Description |
---|---|---|
T | ||
T1 | Solitary skin involvement | |
T1a | A solitary lesion <5 cm diameter | |
T1 b | A solitary >5 cm diameter | |
T2 | Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions | |
T2a | All-disease-encompassing in a <15-cm-diameter circular area | |
T2 b | All-disease-encompassing in a >15- and <30-cm-diameter circular area | |
T2 b | All-disease-encompassing in a >30-cm-diameter circular area | |
T3 | Generalized skin involvement | |
T3a | Multiple lesions involving 2 noncontiguous body regions | |
T3b | Multiple lesions involving ≥3 body regions | |
N | ||
N0 | No clinical or pathologic lymph node involvement | |
N1 | Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement | |
N2 | Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region† that does not drain an area of current or prior skin involvement | |
N3 | Involvement of central lymph nodes | |
M | ||
M0 | No evidence of extracutaneous non–lymph node disease | |
M1 | Extracutaneous non–lymph node disease present |
International Society for Cutaneous Lymphomas (ISCL) / EORTC recommendations for staging evaluation in cutaneous lymphomas other than mycosis fungoides / sezary syndrome[1]
|
---|
Complete history/review of systems and physical examination |
Laboratory studies |
Complete blood count, comprehensive serum chemistries, serum LDH |
Whenever indicated, relevant flow cytometric studies of peripheral blood mononuclear cells |
Imaging studies |
CT of chest, abdomen and pelvis with contrast alone or with whole-body PET (18F-FDG); include CT or ultrasound of neck if clinically indicated |
Whole-body integrated PET/CT (as alternative imaging study to the standard contrast-enhanced CT) |
Bone marrow biopsy and aspirate |
Required in cutaneous lymphomas with intermediate to aggressive clinical behavior as categorized in the WHO-EORTC classification |
Should be considered in cutaneous lymphomas with indolent clinical behavior, but not required unless indicated by other staging assessments |
Additional studies as indicated clinically |
References
- ↑ 1.0 1.1 1.2 1.3 Kim, Y. H.; Willemze, R.; Pimpinelli, N.; Whittaker, S.; Olsen, E. A.; Ranki, A.; Dummer, R.; Hoppe, R. T. (2007). "TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)". Blood. 110 (2): 479–484. doi:10.1182/blood-2006-10-054601. ISSN 0006-4971.